Infectious Disease Consultants — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$45,760	21
2020	Research	$4,312	2
2019	Research	$227,490	35

Breakdown

Who paid Research payments · program years 2019–2021

Janssen Research & Development, LLC $173,055 48 payments
ViiV Healthcare Company $80,417 8 payments
Octapharma USA, Inc. $24,089 2 payments

Studies the money was for Research payments · program years 2019–2021

A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects $80,514 7 payments
Study to Evaluate Efficacy and Safety of Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Regimen Versus Boosted Protease Inhibitor bPI Along With Emtricitabine Tenofovir Disoproxil Fumarate FTCTDF Regimen in Virologically Suppressed HIV1 In $45,760 21 payments
A Phase Iib, Multicenter, Open-Label, Rollover Study Evaluating the Ef $42,024 3 payments
Clinical outcomes of oncedaily Darunavir in patients with Darunavir resistanceassociated mutations $29,773 6 payments
Gam5-28 $24,089 2 payments
A Phase Iib, Dose Ranging Study of Oral Gsk1265744 in Combination With $23,621 1 payment
A Phase 3, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-nave Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Receiving Care in a Test and Treat Model of Care $12,697 12 payments
A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Ad $9,663 2 payments
A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $5,110 2 payments
Clinical outcomes of once daily Darunavir in patients with Darunavir resistance associated mutations $4,312 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.